I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Andor Glaudemans
prof. dr.
Quality in Nuclear Medicine
Andor W.J.M. Glaudemans (Editor), Jitze Medema (Editor), Rudi Dierckx (Editor), Annie van Zanten (Editor), C.T.B.K. Ahaus (Editor)
Linagliptin Reduces Arterial Stiffness and Arterial Inflammation in Persons With Early Type 2 Diabetes: a Double-blind, Randomized Controlled Trial
Stefanie A. de Boer, Hiddo J. Heerspink, Joop D. Lefrandt, Arie M. van Roon, Luis E. Juarez Orozco, Andor W. Glaudemans, Pieter W. Kamphuisen, Riemer H. Slart, Douwe J. Mulder
F-18-FDG PET/CT in the diagnostic workup of infective endocarditis and related intracardiac prosthetic material: A clear message
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.116.176826
Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience
Published in: Clinical Nuclear Medicine
Access to document
10.1097/RLU.0000000000001347
The estrogen derivative 16a-F-18-fluoro-17 beta-estradiol (FES) is a PET tracer that has been used in a variety of preclinical and clinical studies to detect estrogen receptor (ER) expression, mainly in breast cancer, but also for other oncological indications. As a result of the success of these studies and the potential applications of the tracer, FES starts to be implemented in routine clinical practice. However, the number of centers using this tracer is still limited and many nuclear medicine physicians and medical oncologists are still unaware of the possibilities...
Clasina M. Venema, Giulia Apollonio, Geke A. P. Hospers, Carolina P. Schröder, Rudi A. J. O. Dierckx, Erik F. J. de Vries, Andor W. J. M. Glaudemans
Mid-treatment TARC and mid-treatment FGD-PET predict for progression free survival in classical hodgkin lymphom